Abstract
Fifteen to 30 % of OS patients present with lung metastasis at diagnosis, and their 5-year survival rate is still only 20 %, regardless of therapy. Thus, the control of metastasis is still quite hard, and new effective therapy against the metastasis diseases is strongly needed. In this chapter, I would like to summarize the present status of OS metastasis research, especially using our established excellent OS mouse lung metastasis model LM8. Employing this model, we reported several popular candidate molecules as targets for OS lung metastasis, including MMP, motility, VEGF, etc. I also discuss new targets, tissue stiffness, and Twist-1 as future candidates against OS metastasis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006;125:555–81.
Dunn TB, Andervont HB. Histology of some neoplasms and non-neoplastic lesions found in wild mice maintained under laboratory conditions. J Natl Cancer Inst. 1963;31:873–901.
Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283:139–46.
Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H. Establishment and characterization of a murine osteosarcoma (LM8) with high metastatic potential to the lung. Int J Cancer. 1998;76:418–22.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;3:161–74.
Yui Y, Itoh K, Yoshioka K, Naka N, Watanabe M, Hiraumi Y, Matsubara H, Watanabe K, Sano K, Nakahata T, Adachi S. Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8. Clin Exp Metastasis. 2010;27:619–30.
McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet. 2003;361:1959.
Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR. Preclinical drug development must consider the impact on metastasis. Clin Cancer Res. 2009;15:4529–30.
Tanaka T, Yui Y, Naka N, Wakamatsu T, Yoshioka K, Araki N, Yoshikawa H, Itoh K. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8-VEGF is a candidate for anti-metastasis therapy. Clin Exp Metastasis. 2013;30:369–79.
Joyama S, Naka N, Tsukamoto Y, Yoshikawa H, Itoh K. Dendritic cell immunotherapy for lung metastasis from murine osteosarcoma. Clin Orthop Relat Res. 2006;453:318–27.
Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins NL, Acerbi I, Ou G, Wijekoon AC, Levental KR, Gilbert PM, Hwang ES, Chen YY, Weaver VM. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014;20:360–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Itoh, K. (2016). Basic Research for Osteosarcoma Lung Metastasis (LM8). In: Ueda, T., Kawai, A. (eds) Osteosarcoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55696-1_2
Download citation
DOI: https://doi.org/10.1007/978-4-431-55696-1_2
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55695-4
Online ISBN: 978-4-431-55696-1
eBook Packages: MedicineMedicine (R0)